-
Frequent changes in senior management of pharmaceutical companies: Chairman and general manager of many pharmaceutical companies leave
Time of Update: 2021-09-05
Hengrui MedicineHengrui MedicineOn July 9, Hengrui Medicine issued an announcement stating that the company’s board of directors had recently received a resignation report from the company’s chairman and general manager Zhou Yunshu.
-
In the first half of the year, ordinary people had a revenue of 7.46 billion, 11 mergers and acquisitions, and a large volume of self-owned brands
Time of Update: 2021-09-05
Layout: 1,290 new stores, 11 mergers and acquisitions with a value of over 570 million As of June 30, ordinary people’s business covered 22 provinces across the country, with a total of 7680 stores, including 5682 directly-operated stores and 1998 franchised stores.
-
Pfizer's tick-borne encephalitis vaccine TICOVAC receives FDA approval
Time of Update: 2021-09-05
This approval also makes the TICOVAC vaccine the only tick-borne encephalitis vaccine supported by the FDA in the United States, which can protect people of almost all ages from the virus when visiting or living in areas where tick-borne encephalitis is endemic .
-
U.S. FDA grants Vivet/Pfizer VTX-801 fast track qualification
Time of Update: 2021-09-05
VTX-801 is a new type of research gene therapy, which will be evaluated in the Phase 1/2 GATEWAY trial (NCT04537377) to determine the safety, tolerability and pharmacological activity of a single intravenous infusion in the treatment of adults with Wilson disease .
-
This CRO "rolled over" several times: Falsified clinical trial data was sent to prison by the FDA
Time of Update: 2021-09-05
On April 28, the FDA issued a non-compliance notice to Acceleron Pharma, the sponsor who failed to submit the necessary information for clinical trials to the federal registration agency, and warned that it may face fines .
-
CStone Pharmaceuticals' Avnib listing application has been accepted and plans to be included in priority review
Time of Update: 2021-09-05
At the same time, CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has accepted a new drug application (NDA) for Afnib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with IDH1 susceptible mutations.
-
The fifth batch of nationally selected drugs started to go online
Time of Update: 2021-09-05
AnhuiOn July 28, the Anhui Provincial Pharmaceutical Centralized Procurement Service Center issued the "Notice on Declaring the Information of Selected Products Related to the Fifth Batch of National Organizations for Centralized Procurement of Drugs .
-
Mission blessing!
Time of Update: 2021-09-05
At that time, Wang Zhenyi's all-trans retinoic acid treatment method was still only in the test tube experiment stage.
-
Sagimet, a partner of Songli, completes the first phase IIb clinical administration of patients with moderate to severe fibrosis NASH
Time of Update: 2021-09-05
On August 16, Gerry Pharmaceuticals announced that its partner Sagimet Biosciences has completed the first patient administration of its non-alcoholic steatohepatitis (NASH) phase IIb clinical trial (FASCINATE-2) .
FASCINATE-2 is a randomized, double-blind, placebo-controlled phase IIb clinical trial that enrolled approximately 330 NASH patients with moderate to severe fibrosis (F2-F3) .
-
The local Biotech wave is vigorous and the multinational MNC wolves are waiting for the traditional pharmaceutical companies. How to break the situation?
Time of Update: 2021-09-05
In this "involvement" in a race against time, traditional pharmaceutical companies must not only withstand the threats from domestic biotech and multinational giants, but also realize the transformation and upgrading from imitation to innovation while doing generic drugs .
-
Jichuan Pharmaceutical Pudilan Anti-inflammatory Oral Liquid will be withdrawn from Shandong Medical Insurance List
Time of Update: 2021-09-05
’s main product Pudilan Xiaoyan Oral Liquid will be withdrawn from the “Shandong Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs” on November 1, 2021.
-
Pfizer and Flynn Pharmaceuticals accused of manipulation of prices of epilepsy drugs by British CMA
Time of Update: 2021-09-05
CompilationFan DongdongA few days ago, the British Competition and Markets Authority (CMA) accused Pfizer and Flynn Pharmaceuticals of violating antitrust rules and increasing the prices of anti-epileptic treatments, resulting in them charging the British National Health Service (NHS) excessive treatment fees .
-
Hit the East Sunshine!
Time of Update: 2021-09-05
Currently, according to the Insight database, Dongyang Sunshine has two dosage forms of oseltamivir capsules and granules, and has also submitted an application for the marketing of oseltamivir dry suspension, which is currently under review and approval; at the same time, it has also applied for sustained-release tablets.
-
North China Pharmaceutical: nominate candidates for directorship and hire multiple senior executives
Time of Update: 2021-09-05
Liu Xinyan as a candidate for the company’s tenth board of directors and agreed to submit it to the company’s general meeting of shareholders for deliberation .
Liu Xinyan was appointed as the general manager of the company; Mr.
-
500 million oral hypoglycemic drugs in East China all specifications have been reviewed!
Time of Update: 2021-09-05
In January of this year, Huadong submitted an application for the four types of generic listing of canagliflozin tablets, which is expected to become the company's next approved oral hypoglycemic drug .
-
The Medical Insurance Bureau issues a document that concerns all Chinese medicine companies
Time of Update: 2021-09-05
02 Times drive transformation02 Times drive transformationAt the 6th Changbai Mountain International Pharmaceutical and Health Industry Development Forum held in Tonghua·China Medical City, Zhu Xun, former expert of the National New Drug Advisory Committee, said on the current status of the pharmaceutical industry: The problem of transformation is not just traditional pharmaceutical companies, but companies that have already gone public are also facing severe challenges .
-
Wang Guihua, Independent Director of Watson Pharmaceuticals, resigns by-election for Du Shouying as a candidate
Time of Update: 2021-09-05
Wang Guihua applied to resign as an independent director of the company’s second board of directors, chairman of the second board of directors’ remuneration and appraisal committee, member of the audit committee of the second board of directors, and member of the nomination committee of the second board of directors.
-
Can a real estate tycoon without a real controller for many years bring artemisinin into the owner to save this Chinese medicine company?
Time of Update: 2021-09-05
Can Zhulai become the actual controller, can he really save such a single-product Chinese medicine company?01 Domination of Yipin, accounting for 60% of revenue01 Domination of Yipin, accounting for 60% of revenueIn April 2021, Jiaying Pharmaceutical released its 2020 annual report, with annual revenue of 545 million yuan and net profit of 20 million yuan, a year-on-year increase of 116.
-
Announcement of the list of top 100 pharmacies and drug approvals in the country
Time of Update: 2021-09-05
7% of the total national pharmaceutical market during the same period, a year-on-year increase of 0.
From 2016 to 2020, the top 100 pharmaceutical retail companies accounted for an increasing market share.
-
Buchang Pharmaceutical's two injections will be withdrawn from the Heilongjiang Provincial Medical Insurance List at the end of the year
Time of Update: 2021-09-05
On the evening of August 16, Buchang Pharmaceutical issued an announcement stating that the drug compound brain peptide ganglioside injection of the holding subsidiary Jilin Tiancheng Pharmaceutical and the drug Guhong injection of the wholly-owned subsidiary Tonghua Guhong Pharmaceutical will be held in December 2021.
